Abstract
This report examines the market for OTC gastro-intestinal (GI) remedies, last reported by Mintel in November 2004. Since then, market values have grown, albeit at a slower pace than at the start of the decade. A lack of NPD has limited opportunities for market growth and the market is also beginning to feel the pinch of own label development as well as competitive pricing now that more GI products are sold as GSL. On a brighter note, there has been some evidence of consumers trading up into improved formulae and convenience propositions.
The report examines the following hypothesis: Economic and socio-demographic indicators favour future market development particularly if suppliers can bring new and younger consumers into the category by persuading them of the benefits of treatment.
View Cart
